Holen Sie sich die Stockscreener-App
1.4799
1.34%
-0.0101
Schlusskurs vom Vortag:
$1.49
Offen:
$1.49
24-Stunden-Volumen:
237.81K
Relative Volume:
0.25
Marktkapitalisierung:
$157.87M
Einnahmen:
$45.44M
Nettoeinkommen (Verlust:
$-35.43M
KGV:
-4.3526
EPS:
-0.34
Netto-Cashflow:
$-25.39M
1W Leistung:
-4.55%
1M Leistung:
-6.96%
6M Leistung:
-34.38%
1J Leistung:
-66.51%
1-Tages-Spanne:
$1.465
$1.54
1-Wochen-Bereich:
$1.465
$1.61
52-Wochen-Spanne:
$1.26
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Vergleichen Sie MXCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.4799 | 158.94M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
127.07 | 223.39B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
91.97 | 136.67B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
352.53 | 135.88B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.67 | 126.37B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.80 | 48.39B | 5.88B | 1.34B | 799.60M | 2.3489 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Eingeleitet | Stephens | Overweight |
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
Prepare Yourself for Liftoff: MaxCyte Inc (MXCT) - setenews.com
Healthy Upside Potential: MaxCyte Inc (MXCT) - setenews.com
Mirabella Financial Services LLP Has $14.39 Million Stock Position in MaxCyte, Inc. $MXCT - MarketBeat
How MaxCyte Inc. (MYE0) stock compares with market leadersWeekly Stock Report & Smart Swing Trading Techniques - Newser
Is MaxCyte Inc. (MYE0) stock attractive post correction2025 Top Gainers & Daily Price Action Insights - Newser
Can MaxCyte Inc. (MYE0) stock stage a strong rebound this quarterJuly 2025 Sector Moves & Short-Term Swing Trade Alerts - Newser
Is MaxCyte Inc. stock attractive for ETFsTrade Risk Summary & Consistent Return Strategy Ideas - Newser
Why analysts recommend MaxCyte Inc. (MYE0) stockJuly 2025 Trends & Weekly Setup with ROI Potential - Newser
Is MaxCyte Inc. (MYE0) stock dividend growth reliableAnalyst Upgrade & Stepwise Trade Execution Plans - Newser
MaxCyte drives CAR T manufacturing optimization using ExPERT system - Traders Union
Dividend Watch: Why Clearway Energy Inc. (NY4B) stock is upgraded to buyJuly 2025 Volume & Verified Technical Signals - BỘ NỘI VỤ
MaxCyte (MXCT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO - Morningstar
Will MaxCyte Inc. stock attract more institutional investors - moha.gov.vn
The time has not yet come to remove your chips from the table: MaxCyte Inc (MXCT) - setenews.com
MaxCyte aims to optimize CAR T manufacturing with ExPERT system - Traders Union
MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen - Defense World
MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Analysts - MarketBeat
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MSN
MXCT SEC FilingsMaxcyte 10-K, 10-Q, 8-K Forms - Stock Titan
What drives MaxCyte Inc MYE0 stock priceRSI Overbought/Oversold & Daily Tips From Top Market Analysts - earlytimes.in
How MaxCyte Inc. (MYE0) stock reacts to fiscal policiesJuly 2025 Market Mood & Safe Entry Point Alerts - newser.com
Can MaxCyte Inc. (MYE0) stock reach $200 price target2025 Major Catalysts & Weekly High Return Opportunities - newser.com
MaxCyte explores electroporation's role in cell therapy innovation - Traders Union
How MaxCyte Inc. (MYE0) stock behaves under inflation pressureEarnings Recap Summary & High Conviction Buy Zone Picks - newser.com
What Wall Street predicts for MaxCyte Inc. stock priceQuarterly Earnings Report & Risk Managed Investment Entry Signals - newser.com
MaxCyte drives cell engineering focus at Advanced Therapies USA - Traders Union
MaxCyte Announces Major Workforce Reduction Plan - MSN
Is MaxCyte Inc. stock a buy in volatile marketsJuly 2025 Weekly Recap & Reliable Intraday Trade Plans - newser.com
MaxCyte at Stephens Annual Investment Conference: Strategic Restructuring Amid Market Challenges By Investing.com - Investing.com Canada
Will MaxCyte Inc. stock split again soonTrade Risk Report & Daily Profit Maximizing Tips - newser.com
A Look at MaxCyte Inc (MXCT) Shares in the Recent Past Indicates Growth - Setenews
Is MaxCyte Inc. (MYE0) stock nearing a technical breakoutPortfolio Gains Summary & Community Consensus Picks - newser.com
MXCT: SecureDx integration and new product launches position for growth as industry rationalizes - TradingView — Track All Markets
What dividend safety rating applies to MaxCyte Inc. (MYE0) stockIPO Watch & Safe Capital Growth Trade Ideas - newser.com
How MaxCyte Inc. (MYE0) stock trades under stagflation2025 Performance Recap & Entry Point Strategy Guides - newser.com
FY2025 EPS Estimates for MaxCyte Boosted by William Blair - Defense World
Will MaxCyte Inc. (MYE0) stock see valuation expansionJuly 2025 Gainers & Weekly High Return Forecasts - newser.com
How buyback programs support MaxCyte Inc. (MYE0) stockTrade Analysis Summary & Weekly High Return Stock Opportunities - newser.com
What MACD signals say about MaxCyte Inc.July 2025 Patterns & Fast Exit and Entry Strategy Plans - newser.com
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maxcyte Inc-Aktie (MXCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
1.04%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):